Tech Company Financing Transactions
Blueprint Medicines Funding Round
On 4/11/2011, Blueprint Medicines announced $40 million in Series A funding from Third Rock Ventures and private investors.
Transaction Overview
Company Name
Announced On
4/11/2011
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor) (Alexis Borisey)
Proceeds Purpose
Proceeds from the financing will be used to develop new cancer therapies - using the company's proprietary compound library and Insights-to-Validation� Platform - that target the driver molecular aberrations of cancer and emerging resistance mechanisms unique to certain cancer patients.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Sidney St. 200
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffery Albers
Chief Medical Officer
Anthony Boral
Chief Scientific Officer
Marion Dorsch
Executive Vice President
Christoph Lengauer
VP - Bus. Development
Kate Haviland
VP - Finance
Michael Landsittel
VP - General Counsel
Tracey McCain
VP - Human Resources
Debbie Durso-Bumpus
VP - Operations
Christopher Murray
Browse more venture capital transactions:
Prev: 4/11/2011: Bloom Studio venture capital transaction
Next: 4/11/2011: EverFi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs